VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient Glioblastoma.

Autor: Shields JA; Tango Therapeutics, Boston, Massachusetts., Meier SR; Tango Therapeutics, Boston, Massachusetts., Bandi M; Tango Therapeutics, Boston, Massachusetts., Mulkearns-Hubert EE; Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio., Hajdari N; Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio., Ferdinez MD; Tango Therapeutics, Boston, Massachusetts., Engel JL; Tango Therapeutics, Boston, Massachusetts., Silver DJ; Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio., Shen B; Tango Therapeutics, Boston, Massachusetts., Zhang W; Tango Therapeutics, Boston, Massachusetts., Hubert CG; Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio., Mitchell K; Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio., Shakya S; Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio., Zhao SC; Tango Therapeutics, Boston, Massachusetts., Bejnood A; Tango Therapeutics, Boston, Massachusetts., Zhang M; Tango Therapeutics, Boston, Massachusetts., Tjin Tham Sjin R; Tango Therapeutics, Boston, Massachusetts., Wilker E; Tango Therapeutics, Boston, Massachusetts., Lathia JD; Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio., Andersen JN; Tango Therapeutics, Boston, Massachusetts., Chen Y; Tango Therapeutics, Boston, Massachusetts., Li F; Tango Therapeutics, Boston, Massachusetts., Weber B; Tango Therapeutics, Boston, Massachusetts., Huang A; Tango Therapeutics, Boston, Massachusetts., Emmanuel N; Tango Therapeutics, Boston, Massachusetts.

Publikováno v: Cancer research [Cancer Res] 2022 Nov 02; Vol. 82 (21), pp. 4044-4057.